Senate Democrats are pushing for more information about President Trump's drug pricing deals, which they believe are a sham. The legislation would require Health Secretary Robert F. Kennedy Jr. to make terms of the confidential deals public. This is part of a push questioning whether these arrangements really benefit consumers. The deals, known as "most favored nations" deals with 16 pharmaceutical companies, are seen as a signature health policy accomplishment the administration is touting ahead of the midterm elections. However, most of the public is skeptical of the administration's ability to lower drug costs. The administration is refusing to disclose what it agreed to, stating the deals contain confidential and proprietary information.